Home › Bladder Cancer › NCT07225205

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy: A Randomized Controlled Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients greater than 18 years of age and older
* Confirmed urothelial carcinoma on pathology, including muscle invasive, non-muscle invasive, and variant histology
* Patient electing to undergo radical cystectomy with bilateral pelvic lymphadenectomy after counseling with a urologic oncologist.

Exclusion Criteria:

* Patients undergoing radical cystectomy for benign indications (e.g. chronic bladder pain, fistulas, severe lower urinary tract symptoms)
* Patients undergoing radical cystectomy for a non-bladder primary malignancy (e.g. rectal, colon, uterine cancers).
* Patients with extensive locally advanced disease necessitating a pelvic exenteration
* Contraindication to receiving home IVF therapy (i.e. pre-existing cardiac, renal, hepatic dysfunction)
* Unwilling or unable to participate in 30 and 90 day follow-up phone calls.

About the study

Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity. Many complications may be driven by dehydration and it is unclear if a home intravenous fluid (IVF) infusion program post-operatively, which is an accepted standard practice, is beneficial. This study is a single institution randomized controlled trial where patients who choose to undergo radical cystectomy for bladder cancer will be randomized to an Enhanced Recovery After Surgery (ERAS) protocol with a home IVF program, consisting of 1 liter (L) of crystalloid fluid three times per week for four weeks, or ERAS protocol alone. The primary outcome will be 90-day hospital re-admissions, with secondary outcomes including 30 and 90 day complications.

What is being tested

• Intravenous fluids (other)
• ERAS (other)

Sponsor: Johns Hopkins University · Participants: 130 · Started: Nov 1, 2025

Contact the study team

• Tyler S Garman, MD · Phone: 410-955-6100
• Max R Kates, MD · Phone: 410-614-0009

Official record on ClinicalTrials.gov — NCT07225205

Locations in the U.S.

Conditions

• Bladder Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.